top of page


A multi-year initiative


Weill Cornell Medicine and University of Virginia


Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is a comprehensive, multicenter, and multi-investigator study that is advancing the approach to evaluating and managing patients with PF using a precision medicine approach. 

Using genomics, proteomics, and transcriptomics, risk variants that distinguish IPF from non-IPF interstitial lung diseases will be identified, enabling for more accurate diagnoses. In parallel, a first of its kind pharmacogenetic study is defining whether IPF patients with a certain gene variant respond to treatment with N-acetyl-cysteine (NAC), an antioxidant. 

NHLBI and PFF are providing support for the study, which will determine the optimal approach to move the diagnosis and management of PF disorders to a precision medicine era where the right treatment is provided to the right patient. 

Fernando J. Martinez, MD, MS, serves as the principal investigator on the project. In addition to his role in clinical research, he is the Executive Vice Chair of Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital. Translational researcher Imre Noth, MD, Chief of the Division of Pulmonary and Critical Care Medicine at the University of Virginia works closely with Dr. Martinez as a co-principal investigator for this study.

Enlil Therapeutics

Three Lakes Foundation has provided funding to support Enlil Therapeutics in its quest to identify compounds that activate telomerase.

B4PF: Understanding Early Disease

To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.

A Global Collaboration for PF

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.

Additional Programs

bottom of page